Skip to main content
Premium Trial:

Request an Annual Quote

Telo Genomics TeloViewSMM

Telo Genomics has launched the TeloViewSMM system to clinicians in the United States. Combining molecular biology and artificial intelligence, the diagnostic platform enables 6-factor quantitative analysis of 3D telomeres, which are the protective end caps of chromosomes. The company believes TeloView has the potential to characterize multiple cancers, identify their current level of genomic instability and predict their progression. The Company's initial clinical launch is focused on testin in cases of "Smoldering Multiple Myeloma," the precursor for Multiple Myeloma, a malignancy which develops in approximately 50 percent of individuals who start out with SMM. Currently the test is available for physicians to order under an observational study called SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation). While the initial launch will be conducted within a single-site laboratory-developed test model, Telo aims to move eventually into commercial-scale test delivery in partnership with large reference labs where FISH and microscopy resources are available and scalable.